To continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients was compared to matched historical controls (HC).

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

Battini Roberta
2016-01-01

Abstract

To continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpholino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients was compared to matched historical controls (HC).
2016
Mendell, Jerry R; Goemans, Nathalie; Lowes, Linda P; Alfano, Lindsay N; Berry, Katherine; Shao, James; Kaye, Edward M; Mercuri, Eugenio; Battini, Roberta
File in questo prodotto:
File Dimensione Formato  
ANA-79-257.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Creative commons
Dimensione 553.76 kB
Formato Adobe PDF
553.76 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/950129
Citazioni
  • ???jsp.display-item.citation.pmc??? 223
  • Scopus 421
  • ???jsp.display-item.citation.isi??? 365
social impact